leisure time -WSS

leisure time

author：knowledge 2025-09-29 21:22:54 - browse：179

Without question, the new federal law banning surprise billing is achieving its goal of protecting patients from enormous medical bills. But in doing so, the measure, which was initially projected to lower federal spending, appears to be raising costs elsewhere.

The Biden administration’s new progress report on the process for arbitrating disagreements between insurance companies and providers, which covers the first six months of 2023, shows that in over 80% of payment disputes, the arbiter settled on an amount that was more than the median in-network rate for that service. In other words, insurers were ordered to pay more to an out-of-network provider than they’d pay to a contracted one. Not only that, the sheer volume of disputes means the three federal agencies that run the program are devoting much more time to it than expected.

“It raises concerns for folks that envisioned the arbitration process as helping to moderate costs rather than be a tool these companies can leverage to obtain even higher payments,” said Zachary Baron, the director of Georgetown University’s Health Policy and Law Initiative.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The cancer drug shortage isn’t new — and neither are the solutions
Next article： Vertex non

WSS

Venture capital firm's plans to take over Akron hospital face hurdles

Health Care Service Corp to buy Cigna Medicare Advantage plans

Why a market frenzy over new weight loss drugs defies logic

STAT Readout: Friday, Oct. 20 biotech updates

Investment in vaccine development is lagging, report finds

Roche drug slashes death risk in early

entertainment

leisure time

leisure time

Hepatitis C has a cure — but many Americans still lack access to it

Readout LOUD podcast: Live from the 2023 STAT Summit

Moonlake's readout produced a cash windfall. Risks remain

Health Care Service Corp to buy Cigna Medicare Advantage plans

Wildfire smoke exposes gaps in outdoor worker protections

Syphilis numbers in the United States reach record heights

Cancer drug shortages should be causing more outrage

Merck, Johnson & Johnson CEOs will testify on high drug prices

Heart attack and stroke risk calculators need revising

The latest on Bluebird gene therapies, Vertex's pain drug, and ADC FOMO

Wikipedia

Roivant's CEO is a star, but biotech's black hole persists

Biogen walks away from Aduhelm, years after polarizing approval

The latest on Bluebird gene therapies, Vertex's pain drug, and ADC FOMO

Syphilis numbers in the United States reach record heights

Health tech investors get more selective as pandemic boom fades

CZI to create biohub to build anti

entertainment

focus

explore

entertainment